Imatinib-mesylate induced interstitial pneumonitis in two CML patients

Tuberculosis and Respiratory Diseases

Volumn 71, Issue 3, 2011, Pages 210-215

  Kim, Tae Hoon ^a   Kim, Byung Gyu ^a   Cho, Sung Woo ^a   Cho, Sung Kyun ^a   Kim, Hyun Jung ^a   Yuh, Young Jin ^a   Kim, Sung Rok ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Chronic myeloid leukemia; Imatinib mesylate; Lung diseases, interstitial

Indexed keywords

IMATINIB; NILOTINIB; PREDNISONE;

AGED; ARTICLE; ARTIFICIAL VENTILATION; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG FUNCTION TEST; MALE; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

EID: 80054788708     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2011.71.3.210     Document Type: Article

References (11)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
2. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-53. (Pubitemid 46823444)
3. Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 2009;84:287-93.
4. Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, et al. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica 2009;94:1669-75.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7. (Pubitemid 32267972)
6. Ma CX, Hobday TJ, Jen JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc 2003;78:1578-9.
7. Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-4. (Pubitemid 43797313)
8. Rosado MF, Donna E, Ahn YS. Challenging problems in advanced malignancy: case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol 2003;21:3171-3. (Pubitemid 46894001)
9. Seki N, Ito A, Watanabe K, Shibakuki R, Seto T, Uematsu K, et al. Irreversible imatinib-induced pneumonitis following long-term imatinib administration. Intern Med 2007;46:1941-2.
10. Lee JW, Kim HJ, Kim KJ, Shin KC, Hong YH, Chung JH, et al. A case of imatinib-mesylate associated hypersensitivity pneumonitis. Tuberc Respir Dis 2005;59:423-6. (Pubitemid 43014779)
11. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56. (Pubitemid 46630633)